Head Office +91 8729085230

Guru Angad Nagar,
New Delhi 110092

09.00 to 18.00 Monday to Saturday

Amyotrophic Lateral Sclerosis (ALS) Market Outline: 

The 9MM Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market is expected to offer an $ opportunity of USD 682.1 Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR 7.04% over the projected period (2023-2033). And by the end of 2033, the market is expected to touch USD XX Million.

Pipeline drugs expected to provide an opportunity of USD 3,706.8 million during the forecast year i.e. (2023-2033)

Disease Overview

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder, identified by degeneration of motor neuron in spinal cord and brain, leading to lack of control over muscles. Affected patients identified with symptoms such Limb Weakness, Muscle Cramps and Twitching, Speech and Swallowing Difficulties, Cognitive and Behavioral Changes and respiratory problem. 

Disease Classification:

  • Sporadic ALS accounts for around 90-94% of cases, primarily attributed to no genetic link.
  • Familial ALS accounts for 6-10% of cases

Report has deeply investigated patient’s presentation and tailored treatment

Report has Covered Granular-level Analysis Across Each Mapped Market

Amyotrophic Lateral Sclerosis (ALS) Disease Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)

  • This section explored the epidemiology associated with Amyotrophic Lateral Sclerosis (ALS) across regions
  • Experts indicated prevalence increased significantly across regions, but gaps in estimates still persist. 
  • Our research report has provided crystal clear view of prevalent pool across regions. Since epidemiology estimation accompanied with lot of complexity, our report has streamlined the estimation process for enhancing market understanding.
  • Report has also highlighted, impact of improvements in diagnosis, (diagnosis rate %).  

Amyotrophic Lateral Sclerosis (ALS) Cases: 9MM 

  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in 9MM
  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in United States
  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in China
  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in India
  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in Japan
  • Amyotrophic Lateral Sclerosis (ALS) accounts for XX million cases in Rest of World

Treatment Landscape: 

This report section deals with the treatment strategies adopted by healthcare professional while dealing across patients’ segments.  Also provided gaps in current treatment and upcoming treatment options. 

  • Treatment of Amyotrophic Lateral Sclerosis (ALS)’s requires holistic framework to address diverse set of patients. Collaboration among various specialties is imperative to devise tailoring treatment plan. Efforts to encourage diagnosis rate and advocacy at patient and physician level is crucial to provide better therapeutic options.
  • Report section covers detailed around various types of available treatments
  • Also covers patient segment targeted by each therapy type: This section address concerns regarding unaddressed patient pool 
  • Several companies and institutions collaborating to bring out the appropriate treatment solutions
  • Our report analysis revealed that, there are tremendous opportunities exist in the market in order to close the current market gaps
  • Recent clinical guidelines enable the streamlining the treatment approaches
  • Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.

Patient Segment Coverage:

DrugTargeted Patient Segment Analysis
Disease-Modifying TherapiesXX
Symptomatic TreatmentsXX
Experimental TreatmentXX

Upcoming Therapy Assessment (Pipeline Analysis)

  • Report also provided promising therapy assessment including existing therapies, and upcoming therapy
  • Novel drug target assessment
  • Comparable efficacy and safety profiles of key drugs prescribed in each mapped geography
  • Expected launch of key pipeline assets
  • Report also investigated novel therapy development
  • Experts Opinion on the matter of accepting novel treatment options
  • Promising molecules advantages offer over existing therapy
  • Impact assessment of pipeline assets
  • Drug analogue analysis
  • Expected annual cost of therapy
  • Market space expected to be captured by emerging therapeutic options

Market Segmentation Analysis by:

  • By Disease Type
    • By Inheritance Pattern 
      • Sporadic ALS (sALS)
      • Familial ALS (fALS)
    • By Site of Onset
      • Limb-Onset ALS
      • Bulbar-Onset ALS
    • By Specific Genetic Mutations
      • C9orf72-Related ALS
      • SOD1-Related ALS
      • TARDBP (TDP-43) and FUS-Related ALS
  • By Treatment
    • Disease-Modifying Therapies
      • Riluzole (Rilutek)
      • Edaravone (Radicava)
      • Others
    • Symptomatic Treatments
      • Muscle Relaxants
      • Antidepressants
      • Medications for Excessive Saliva
      • Pseudobulbar Affect
    • Experimental Treatment
      • Gene Therapy
      • Stem Cell Therapy
      • Novel Drug Treatments

Market Enablers: Explored in the report

  • Untreated Prevalent Pool of Amyotrophic Lateral Sclerosis (ALS)
  • Huge medical unmet need
  • Advancements in diagnosis tools
  • Development of novel treatment options
  • Advent of emerging therapy for developing tailoring treatment
  • Emergence of Targeted Therapies

Market Challenges: Explored in the report

  • Limited Treatment Options Approved by Regulatory bodies
  • Access to Care and Treatment in Emerging Market
  • Research and development gaps
  • Cost of therapy
  • Lack of adequate treatment compliance and adherence
  • Lack of Consensus among existing clinical guidelines and awareness among the population

Mapped Geography: Nine Major Markets (9MM) 

Report has fragmented the total market into five regions such as:

  • United States
  • 5-Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Rest of Europe
  • China
  • Japan
  • India
  • RoW (Rest of World)

Each mapped region has been examined at granular level based on below parameters:

United States Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Market Unmet Need Analysis

5-Europe Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

By Country

  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

China Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

India Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

Japan Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

Rest of the World Amyotrophic Lateral Sclerosis (ALS) Drug Treatment Market

  • Market Size and Forecast Model 2023-2033
  • Disease Overview
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Drug Treatment Adherence and Compliance Rate (%)
  • Annual Cost of Therapy
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

Competitive Landscape (Existing and Pipeline Players): 

Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Company Profiles:

Pharmaceutical Drug Companies (Marketed + Pipeline)

  • Roche (Genentech)
  • Mitsubishi Tanabe Pharma Corporation
  • Amylyx Pharmaceuticals
  • Cytokinetics
  • Biogen
  • Neurocrine Biosciences
  • Innate Pharma
  • Vertex Pharmaceuticals
  • Acorda Therapeutics
  • Prilenia Therapeutics
  • Orion Corporation
  • Zynerba Pharmaceuticals
  • Brainstorm-Cell Therapeutics
  • Phoenix Neurological Associates, LTD
  • Eisai Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • AZTherapies, Inc.
  • Annexon, Inc.
  • Verge Genomics
  • Sangamo Therapeutics
  • Immunity Pharma Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Corcept Therapeutics
  • Ono Pharmaceutical Co. Ltd
  • Knopp Biosciences

Reason to buy this report:

  • Fostering Understanding on Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  • In Order to Understand the Market Potential 
  • Opportunity Analysis (exist in the market for players)
  • Clinical Developments in the market
  • To Know Current and Future Market Trends
  • Key Players and their Key Strategic Move